APA (7th ed.) Citation

Reardon, D. A., Kim, T. M., Frenel, J., Simonelli, M., Lopez, J., Subramaniam, D. S., . . . Massard, C. (2021). Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial. Cancer (0008543X), 127(10), 1620. https://doi.org/10.1002/cncr.33378

Chicago Style (17th ed.) Citation

Reardon, David A., et al. "Treatment with Pembrolizumab in Programmed Death Ligand 1–positive Recurrent Glioblastoma: Results from the Multicohort Phase 1 KEYNOTE‐028 Trial." Cancer (0008543X) 127, no. 10 (2021): 1620. https://doi.org/10.1002/cncr.33378.

MLA (9th ed.) Citation

Reardon, David A., et al. "Treatment with Pembrolizumab in Programmed Death Ligand 1–positive Recurrent Glioblastoma: Results from the Multicohort Phase 1 KEYNOTE‐028 Trial." Cancer (0008543X), vol. 127, no. 10, 2021, p. 1620, https://doi.org/10.1002/cncr.33378.